Literature DB >> 11274022

Optimization of beta-quantification methods for high-throughput applications.

T G Cole1, C A Ferguson, D W Gibson, W L Nowatzke.   

Abstract

BACKGROUND: Risk of cardiovascular disease is assessed, in part, by laboratory measurement of the concentrations of several lipoproteins. beta-Quantification is a method of lipoprotein measurement that uses ultracentrifugation to partially separate lipoprotein classes. Although beta-quantification is used largely in clinical and basic research, methods have not been described to allow the analysis of a large number of small-volume specimens with a short turnaround time. We report two variations of the traditional 5-mL method used by the Lipid Research Clinics Program that overcome these shortcomings.
METHODS: Two lower-volume modifications of the traditional 5-mL beta-quantification method were developed. The methods used either 1 or 0.23 mL of specimen and required substantially less time for analysis (20 and 6 h, respectively) than the 5-mL method (2.5 days). The goal was to develop ultracentrifugation methods such that the concentration of cholesterol in the bottom fraction, from which LDL-cholesterol concentration is calculated, agreed with the 5-mL method. Fresh serum specimens (n = 45) were analyzed by the three methods to determine comparability of the methods based on the recovery of cholesterol in the bottom fraction after ultracentrifugation. To evaluate intrarun precision, replicate specimens (n = 17) were analyzed in a single run for each method. This experiment also evaluated how quickly the fractions would remix after separation by ultracentrifugation. For the 1-mL method, accuracy of the measurement of LDL- and HDL-cholesterol concentrations and the interrun precision were established by analysis of frozen serum specimens provided by the CDC, which established target values for the pools using reference methods.
RESULTS: No clinically significant differences in cholesterol concentrations in the bottom fraction were observed for the 1- and 0.23-mL methods, which had mean biases of 0.8% and 1.5% relative to the 5-mL method, respectively. Intra- and interrun variability was acceptable for each method, e.g., <1.8% for cholesterol in the bottom fraction. Ultracentrifuged specimens were stable for at least 4 h with no evidence of contamination of cholesterol in the bottom fraction. For comparison specimens provided by the CDC, the 1-mL method met the accuracy and precision goals of the National Cholesterol Education Program for the measurement of HDL- and LDL-cholesterol concentrations (goals: total error <13% and <12%, respectively), with total errors of 6.45% and 5.43%, respectively.
CONCLUSIONS: Both the 1- and 0.23-mL beta-quantification methods are suitable substitutes for the traditional 5-mL method for use in clinical and basic research for the determination of LDL-cholesterol concentration. Both methods provide much higher throughput and require substantially less specimen volume. The 0.23-mL method can be performed in 1 day, but it is slightly less precise than the 1-mL method. In our laboratory setting, as many as 80 specimens are routinely processed per day using the 1-mL method.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274022

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Serum LDL- and HDL-cholesterol determined by ultracentrifugation and HPLC.

Authors:  Jun Dong; Hanbang Guo; Ruiyue Yang; Hongxia Li; Shu Wang; Jiangtao Zhang; Wenxiang Chen
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

2.  Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile.

Authors:  Latisha Love-Gregory; Richard Sherva; Timothy Schappe; Jian-Shen Qi; Jennifer McCrea; Samuel Klein; Margery A Connelly; Nada A Abumrad
Journal:  Hum Mol Genet       Date:  2010-10-08       Impact factor: 6.150

3.  LDL cholesterol performance of beta quantification reference measurement procedure.

Authors:  Masakazu Nakamura; Yuzo Kayamori; Hiroyasu Iso; Akihiko Kitamura; Masahiko Kiyama; Isao Koyama; Kunihiro Nishimura; Michikazu Nakai; Hiroyuki Noda; Mahnaz Dasti; Hubert W Vesper; Yoshihiro Miyamoto
Journal:  Clin Chim Acta       Date:  2014-02-28       Impact factor: 3.786

4.  Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.

Authors:  Michael Davidson; Sherry Xueyu Liu; Philip Barter; Eliot A Brinton; Christopher P Cannon; Antonio M Gotto; Elizabeth T Leary; Sukrut Shah; Michael Stepanavage; Yale Mitchel; Hayes M Dansky
Journal:  J Lipid Res       Date:  2012-11-19       Impact factor: 5.922

5.  Comparison of calculated versus directly-measured low-density lipoprotein-cholesterol: An evaluation of ten formulas for an HIV-positive population in Sub-Saharan Africa.

Authors:  Ifeyinwa Osegbe; Martin Ugonabo; Chinwe Chukwuka; Ijeoma Meka; Nnamdi Nwosu
Journal:  J Lab Physicians       Date:  2017 Apr-Jun

6.  Developing a Modified Low-Density Lipoprotein (M-LDL-C) Friedewald's Equation as a Substitute for Direct LDL-C Measure in a Ghanaian Population: A Comparative Study.

Authors:  Richard K D Ephraim; Emmanuel Acheampong; Swithin M Swaray; Enoch Odame Anto; Hope Agbodzakey; Prince Adoba; Bright Oppong Afranie; Emmanuella Nsenbah Batu; Patrick Adu; Linda Ahenkorah Fondjo; Samuel Asamoah Sakyi; Beatrice Amoah
Journal:  J Lipids       Date:  2018-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.